Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.56 |
| ▸ | HTR2A | P28223 | 10/20 | 0.56 |
| ▸ | HTR2B | P41595 | 7/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18413086 | 0.81 | HTR2A (0.42) | HTR2CHTR2AHTR2BNOTUM | |
| Hydrochloric Acid SCHEMBL27555071 | 0.76 | HTR2C (0.44) | HTR2CHTR2AHTR2BPARP1 | |
| SCHEMBL27716469 | 0.74 | HTR2C (0.45) | HTR2CHTR2AHTR2BPARP1 | |
| SCHEMBL6713653 | 0.72 | HTR2C (1.00) | HTR2CHTR2AHTR2B | |
| SCHEMBL14540409 | 0.71 | HTR2C (0.43) | HTR2CHTR2AHTR2B | |
| SCHEMBL27569386 | 0.70 | HTR2C (0.51) | HTR2CHTR2AHTR2BNOTUM | |
| SCHEMBL2869637 | 0.69 | HTR2C (0.58) | HTR2CHTR2AHTR2BNOTUMHTR1A | |
| SCHEMBL18175772 | 0.69 | HTR2C (0.53) | HTR2CHTR2AHTR2BADRB1 | |
| SCHEMBL11102106 | 0.68 | HTR2C (0.45) | HTR2CHTR2AHTR2BHTR6ADRB1 | |
| SCHEMBL1673259 | 0.67 | AADAT (0.46) | HTR2CHTR2AHTR2BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358432-B2 | Piperdinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358432-B2 | Piperdinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRD1 | HTR2C 71/4885HTR2A 42/4885HTR2B 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.